Table 2. Reported grade 3 or 4 toxicities during gemcitabine/bexarotene treatment cycles 1–4 or within 30 days of stopping combination treatment, as-treated population.
| |
Grade 3 (N=35) |
Grade 4 (N=35) |
Total (N=35) |
|---|---|---|---|
| No. (%) | No. (%) | No. (%) | |
| Any toxicity (each patient counted once) |
24 (68.6) |
8 (22.9) |
25 (71.4) |
| Any haematological toxicity (each patient counted once) |
13 (37.1) |
4 (11.4) |
14 (40.0) |
| Neutropaenia | 8 (22.9) | 3 (8.6) | 11 (31.4) |
| Leucopaenia | 4 (11.4) | 1 (2.9) | 5 (14.3) |
| Thrombocytopaenia | 1 (2.9) | 1 (2.9) | 2 (5.7) |
| Anaemia |
1 (2.9) |
0 (0.0) |
1 (2.9) |
| Any non-haematological toxicity (each patient counted once) |
15 (42.9) |
4 (11.4) |
17 (48.6) |
| Hyperlipidaemia | 7 (20.0) | 3 (8.6) | 10 (28.6) |
| Hepatotoxicity | 3 (8.6) | 0 (0.0) | 3 (8.6) |
| Fatigue | 2 (5.7) | 0 (0.0) | 2 (5.7) |
| Infection | 2 (5.7) | 0 (0.0) | 2 (5.7) |
| Skin rash | 2 (5.7) | 0 (0.0) | 2 (5.7) |
| Renal failure | 0 (0.0) | 1 (2.9) | 1 (2.9) |
| Aching muscles and joints | 1 (2.9) | 0 (0.0) | 1 (2.9) |
| Dry skin | 1 (2.9) | 0 (0.0) | 1 (2.9) |
| Fever | 1 (2.9) | 0 (0.0) | 1 (2.9) |
| Insomnia | 1 (2.9) | 0 (0.0) | 1 (2.9) |
| Obstruction GI – bowel | 1 (2.9) | 0 (0.0) | 1 (2.9) |
| Oedema | 1 (2.9) | 0 (0.0) | 1 (2.9) |